10-Q: Applied DNA Sciences Reports Q1 2025 Results, Revenue Up but Losses Persist Amid Strategic Shift

Applied DNA Sciences saw revenue growth in Q1 2025 but continues to experience net losses as it focuses on Therapeutic DNA Production Services and exits its DNA Tagging and Security Products and Services business.

Summary

• Applied DNA Sciences reported a net loss of $2.67 million for the three months ended December 31, 2024, compared to a net loss of $1.13 million for the same period in 2023.
• Total revenue increased to $1.20 million from $0.89 million year-over-year.
• The company is focusing on Therapeutic DNA Production Services and MDx Testing Services.
• Applied DNA Sciences is exiting its DNA Tagging and Security Products and Services business, which will result in one-time personnel-related charges of approximately $300,000 in the next quarter.
• A workforce reduction of approximately 20% was completed in January 2025, expected to reduce annual payroll costs by approximately 13%.
• The company's cash and cash equivalents were $9.29 million as of December 31, 2024.
• The company completed a registered direct offering in October 2024, raising net proceeds of approximately $5.7 million.
• There is substantial doubt about the company's ability to continue as a going concern for one year from the issuance of these financial statements.
• The company needs to raise additional capital and generate revenues to continue operations.

Sentiment

Score: 4

Explanation: While revenue increased, the increasing net loss and going concern warning temper any positive sentiment. The strategic shift and capital raise add uncertainty.

Positives

• Total revenue increased by 34% year-over-year.
• Product and service revenues saw significant increases.
• Gross profit margin improved substantially.
• Selling, general, and administrative expenses decreased.
• The company secured $5.7 million in net proceeds from a registered direct offering.
• The company's Linea IVT platform combines Spindles proprietary high-performance RNAP, now marketed by the Company as Linea RNAP, with our enzymatically produced LineaDNA IVT templates.
• GMP site 1 achieved operation status as of January 31, 2025.

Negatives

• The company continues to experience net losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is exiting its DNA Tagging and Security Products and Services business segment, incurring one-time charges.
• Clinical laboratory service revenues decreased slightly.
• The company is not in compliance with Nasdaqs Bid Price Rule.

Risks

• The company's ability to continue as a going concern is dependent on raising capital and generating revenues.
• The company's non-compliance with Nasdaq's Bid Price Rule may lead to delisting.
• The company may need to issue additional shares of common stock, preferred stock, or other debt or equity securities, which would dilute ownership.
• The company's Laboratory Developed Tests may become subject to additional regulatory requirements.
• The company faces risks associated with product development, clinical trials, and regulatory approvals.
• The company faces risks associated with commercialization of products and services.
• The company faces risks associated with economic and industry conditions.
• The company faces risks associated with the volatility of, and decline in, our stock price.
• The company faces risks associated with our ability to obtain the necessary financing to fund our operations and effect our strategic development plan.

Future Outlook

The company plans to focus on the Therapeutic DNA Production Services, including expanding its CDMO for synthetic DNA and associated enzymes. The company expects to modify and refine its business strategy based on available opportunities. The company plans to implement a reverse stock split of its outstanding securities to regain compliance with the Bid Price Rule and to comply with the provisions of the October Purchase Agreement.

Industry Context

The company is positioning itself to capitalize on the growing market for mRNA therapies and nucleic acid-based therapeutics. The company's LineaDNA platform is presented as an alternative to traditional plasmid-based DNA manufacturing. The company is also expanding its clinical testing services for the detection of Mpox.

Comparison to Industry Standards

• The document mentions that as of the fourth quarter of calendar year 2024, there were 4,238 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use DNA in their manufacturing process.
• The document mentions that as of the fourth quarter of calendar 2024, there were over 450 mRNA therapies under development, with the majority of these therapies (65%) in the preclinical stage (Source: ASGCT Gene, Cell & RNA Therapy Landscape: Q4 2024 Quarterly Report).

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of delisting from Nasdaq.
• Employees experienced a 20% workforce reduction.
• Customers of the DNA Tagging and Security Products and Services business will be impacted by the company's exit from that segment.
• The company's focus on Therapeutic DNA Production Services may benefit customers in that market.

Next Steps

• The company plans to seek Warrant Stockholder Approval at a special meeting of stockholders.
• The company intends to implement a reverse stock split of its outstanding securities to regain compliance with the Bid Price Rule.
• The company plans to continue to service certain of its existing DNA Tagging and Security Products and Services customer contracts.
• The company plans to leverage its PGx Testing Services to provide PGx testing services to large entities, self-insured employers and healthcare providers, as well as concierge healthcare providers.
• The company plans to offer several quality grades of Linea DNA, each of which will have different permitted uses.
• The company plans to utilize its current and planned DNA manufacturing capabilities in GMP Site 1 and/or GMP Site 2 to convert new and existing LineaDNA IVT template customers to LineaDNA IVT platform customers to increase the Companys mRNA-related TAM.

Key Dates